SMA
Clinical trials for SMA explained in plain language.
Never miss a new study
Get alerted when new SMA trials appear
Sign up with your email to follow new studies for SMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a muscle-boosting antibody help people with spinal muscular atrophy over the long haul?
Disease control OngoingThis trial tests the long-term safety and effectiveness of apitegromab, an investigational antibody that blocks myostatin, a protein that limits muscle growth. People with type 2 or type 3 spinal muscular atrophy who completed earlier apitegromab studies can join. Researchers wil…
Matched conditions: SMA
Phase 3 • Sponsor: Scholar Rock, Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug shows promise for SMA patients in major trial
Disease control OngoingThis study tests whether adding taldefgrobep alfa to standard SMA treatments can improve muscle function in people with spinal muscular atrophy (SMA). About 269 participants, both walkers and non-walkers, will receive either the drug or a placebo for 48 weeks. The main goal is to…
Matched conditions: SMA
Phase 3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Early access to experimental SMA drug apitegromab offered before approval
Disease control Expanded access (ended)This expanded access program provides apitegromab, an experimental drug that blocks myostatin to help maintain muscle strength, to eligible patients with spinal muscular atrophy (SMA) before it is officially approved. Participants must be at least 2 years old and have a confirmed…
Matched conditions: SMA
Sponsor: Scholar Rock, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC